Kidney Week

Abstract: SA-PO1081

Intradialytic Parenteral Nutrition Reduces Recurrent Hospitalizations in Patients on Hemodialysis

Session Information

• Kidney Replacement Therapy and Care Delivery Innovations
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

• 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

• Slusser, Maiya, Patient Care America, Pompano Beach, Florida, United States

Maiya Slusser, MS, RD, RDN

• Kirilina, Darina, Columbia University, New York, New York, United States

Darina Kirilina, MS

• Wang, Chunhui, Columbia University, New York, New York, United States

Chunhui Wang, MD, MPH

• Sabatino, Alice, Karolinska Institutet, Stockholm, Stockholm County, Sweden

Alice Sabatino, MS, RD

• Avesani, Carla Maria, Karolinska Institutet, Stockholm, Stockholm County, Sweden

Carla Maria Avesani, PhD, RD

• Steiber, Alison Leah, University Hospitals Health System, Cleveland, Ohio, United States

Alison Leah Steiber, PhD

• Stenvinkel, Peter, Karolinska Institutet, Stockholm, Stockholm County, Sweden

Peter Stenvinkel, MD, PhD

• Kurlansky, Paul, Columbia University, New York, New York, United States

Paul Kurlansky, MD

• Fouque, Denis, Universite Lyon 1 Faculte de Medecine Lyon-Est, Lyon, Auvergne-Rhône-Alpes , France

Denis Fouque, MD, PhD

• Hardy, Mark A., Columbia University, New York, New York, United States

Mark A. Hardy, MD

• Hehenberger, Karin, Patient Care America, Pompano Beach, Florida, United States

Karin Hehenberger, MD, PhD

Background

Intradialytic parenteral nutrition (IDPN) has been shown to improve serum albumin levels; a strong surrogate marker of hospitalization risk in patients on hemodialysis (HD). However, real-world outcomes data remain limited. This study evaluated the association between the use of IDPN and recurrent hospitalizations in a large in-center hemodialysis (ICHD) cohort.

Methods

Observational longitudinal study with a follow-up of 12 months. Patients receiving ICHD three times weekly with concurrent IDPN between May 2018 and April 2023 were identified from a proprietary database of patients treated in the United States. A comparator cohort was derived from the United States Renal Data System (USRDS) 2018-2020 using a stepwise selection process. Inverse probability of treatment weighting (IPTW) was applied to balance baseline characteristics. Recurrent hospitalizations were analyzed using the Wei–Lin–Weissfeld (WLW) marginal model, implemented as a Cox proportional hazards model stratified by event order (readmission number), with each event treated as a separate process. All analyses were conducted using R version 4.3.1.

Results

After IPTW, the effective sample size was 6,771, including 994 IDPN-treated patients and 5,778 USRDS controls (Table 1). Patients in the USRDS cohort experienced a substantially higher risk of recurrent hospitalization compared with those receiving IDPN at both 6 months and 1 year (6 months: HR 5.60 [95% CI 4.66–6.71]; 1 year: HR 5.61 [95% CI 4.79–6.56]; both p <0.001)

Conclusion

IDPN treatment was strongly associated with a substantial reduction in recurrent hospitalization risk among patients undergoing ICHD. These findings support IDPN as an effective nutritional intervention that may reduce healthcare utilization and associated costs in appropriately selected patients.

Funding

• Commercial Support – Baxter Healthcare Corporation, Clinical Nutrition Division; Patient Care America